{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T21:19:04Z","timestamp":1779916744289,"version":"3.53.1"},"reference-count":29,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2005,8,1]],"date-time":"2005-08-01T00:00:00Z","timestamp":1122854400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2005,8,1]],"date-time":"2005-08-01T00:00:00Z","timestamp":1122854400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2005,8]]},"DOI":"10.1016\/j.hoc.2005.05.008","type":"journal-article","created":{"date-parts":[[2005,8,4]],"date-time":"2005-08-04T15:57:38Z","timestamp":1123171058000},"page":"751-763","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Secondary Central Nervous System Lymphoma: Risk Factors and Prophylaxis"],"prefix":"10.1016","volume":"19","author":[{"given":"Silvia","family":"Montoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T. Andrew","family":"Lister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.hoc.2005.05.008_bib1","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1097\/00000421-199112000-00004","article-title":"Central nervous system involvement in patients with diffuse aggressive non-Hodgkin's lymphoma","volume":"14","author":"Bashir","year":"1991","journal-title":"Am J Clin Oncol"},{"issue":"2","key":"10.1016\/j.hoc.2005.05.008_bib2","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1023\/A:1008260120532","article-title":"For which patients with aggressive non-Hodgkin's lymphoma is prophylaxis for central nervous system disease mandatory?","volume":"9","author":"Bos","year":"1998","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.hoc.2005.05.008_bib3","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1182\/blood.V91.4.1178","article-title":"Risk factors, treatment, and outcome of central nervous system recurrence in adults with intermediate-grade and immunoblastic lymphoma","volume":"91","author":"van Besien","year":"1998","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.hoc.2005.05.008_bib4","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1023\/A:1008418727472","article-title":"Peripheral T-cell lymphomas: initial features, natural history, and prognostic factors in a series of 174 patients diagnosed according to the R.E.A.L. classification","volume":"9","author":"Lopez-Guillermo","year":"1998","journal-title":"Ann Oncol"},{"issue":"5\u20136","key":"10.1016\/j.hoc.2005.05.008_bib5","doi-asserted-by":"crossref","first-page":"571","DOI":"10.3109\/10428199909058415","article-title":"Isolated central nervous system relapse in aggressive non-Hodgkin's lymphoma: the Bologna experience","volume":"32","author":"Zinzani","year":"1999","journal-title":"Leuk Lymphoma"},{"issue":"8","key":"10.1016\/j.hoc.2005.05.008_bib6","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1200\/JCO.1999.17.8.2479","article-title":"CNS involvement in primary mediastinal large B-cell lymphoma","volume":"17","author":"Bishop","year":"1999","journal-title":"J Clin Oncol"},{"issue":"16","key":"10.1016\/j.hoc.2005.05.008_bib7","doi-asserted-by":"crossref","first-page":"3018","DOI":"10.1200\/JCO.2000.18.16.3018","article-title":"CNS involvement in children with newly diagnosed non-Hodgkin's lymphoma","volume":"18","author":"Sandlund","year":"2000","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.hoc.2005.05.008_bib8","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1023\/A:1008394827806","article-title":"Incidence and risk factors of central nervous system relapse in histologically aggressive non-Hodgkin's lymphoma uniformly treated and receiving intrathecal central nervous system prophylaxis: a GELA study on 974 patients","volume":"11","author":"Haioun","year":"2000","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.hoc.2005.05.008_bib9","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1093\/annonc\/mdf175","article-title":"Central nervous system involvement following diagnosis of non-Hodgkin's lymphoma: a risk model","volume":"13","author":"Hollender","year":"2002","journal-title":"Ann Oncol"},{"key":"10.1016\/j.hoc.2005.05.008_bib10","first-page":"325a","article-title":"Central nervous system (CNS) involvement in mantle cell lymphoma (MCL)","author":"Ferrer","year":"2004","journal-title":"The Hematology Journal"},{"issue":"1","key":"10.1016\/j.hoc.2005.05.008_bib11","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1093\/annonc\/mdh013","article-title":"Incidence and risk factors for central nervous system occurrence in elderly patients with diffuse large-B-cell lymphoma: influence of rituximab","volume":"15","author":"Feugier","year":"2004","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.hoc.2005.05.008_bib12","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1182\/blood.V84.5.1361.1361","article-title":"A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group","volume":"84","author":"Harris","year":"1994","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.hoc.2005.05.008_bib13","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1200\/JCO.1998.16.8.2780","article-title":"New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes","volume":"16","author":"Armitage","year":"1998","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.hoc.2005.05.008_bib14","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1200\/JCO.1989.7.2.186","article-title":"Non-Hodgkin's lymphomas of childhood: an analysis of the histology, staging, and response to treatment of 338 cases at a single institution","volume":"7","author":"Murphy","year":"1989","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.hoc.2005.05.008_bib15","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1200\/JCO.2000.18.10.2017","article-title":"Outcome of CNS disease at diagnosis in disseminated small noncleaved-cell lymphoma and B-cell leukemia: a Children's Cancer Group study","volume":"18","author":"Gururangan","year":"2000","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.hoc.2005.05.008_bib16","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1002\/cncr.10699","article-title":"Prophylactic intrathecal methotrexate and hydrocortisone reduces central nervous system recurrence and improves survival in aggressive non-Hodgkin lymphoma","volume":"95","author":"Tomita","year":"2002","journal-title":"Cancer"},{"issue":"9","key":"10.1016\/j.hoc.2005.05.008_bib17","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1080\/1042819021000006475","article-title":"Intrathecal chemotherapy alone is inadequate central nervous system prophylaxis in patients with intermediate-grade non-Hodgkin's lymphoma","volume":"43","author":"Chua","year":"2002","journal-title":"Leuk Lymphoma"},{"issue":"11","key":"10.1016\/j.hoc.2005.05.008_bib18","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1200\/JCO.1994.12.11.2415","article-title":"Autologous bone marrow transplantation for patients with non-Hodgkin's lymphoma and CNS involvement: those transplanted with active CNS disease have a poor outcome: a report by the European Bone Marrow Transplant Lymphoma Registry","volume":"12","author":"Williams","year":"1994","journal-title":"J Clin Oncol"},{"issue":"13","key":"10.1016\/j.hoc.2005.05.008_bib19","doi-asserted-by":"crossref","first-page":"4284","DOI":"10.1182\/blood-2003-02-0542","article-title":"Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma","volume":"102","author":"Tilly","year":"2003","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.hoc.2005.05.008_bib20","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1002\/1097-0142(19860301)57:5<971::AID-CNCR2820570516>3.0.CO;2-X","article-title":"Central nervous system prophylaxis with combined intravenous and intrathecal methotrexate in diffuse lymphoma of aggressive histologic type","volume":"57","author":"Perez-Soler","year":"1986","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.hoc.2005.05.008_bib21","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1200\/JCO.1996.14.3.941","article-title":"CNS involvement in mantle-cell lymphoma","volume":"14","author":"Montserrat","year":"1996","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.hoc.2005.05.008_bib22","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1182\/blood.V92.2.411","article-title":"Early intensification of intrathecal chemotherapy virtually eliminates central nervous system relapse in children with acute lymphoblastic leukemia","volume":"92","author":"Pui","year":"1998","journal-title":"Blood"},{"issue":"2\u20133","key":"10.1016\/j.hoc.2005.05.008_bib23","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1023\/A:1005963732481","article-title":"Meningeosis leukaemica in adult acute lymphoblastic leukaemia","volume":"38","author":"Gokbuget","year":"1998","journal-title":"J Neurooncol"},{"issue":"3","key":"10.1016\/j.hoc.2005.05.008_bib24","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1200\/JCO.2000.18.3.547","article-title":"Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia","volume":"18","author":"Kantarjian","year":"2000","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.hoc.2005.05.008_bib25","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/bjc.1990.317","article-title":"High dose cytosine arabinoside in the initial treatment of adults with acute lymphoblastic leukaemia","volume":"62","author":"Rohatiner","year":"1990","journal-title":"Br J Cancer"},{"issue":"6","key":"10.1016\/j.hoc.2005.05.008_bib26","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1182\/blood.V54.6.1249.1249","article-title":"Central nervous system relapse in malignant lymphomas: risk factors and implications for prophylaxis","volume":"54","author":"Litam","year":"1979","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.hoc.2005.05.008_bib27","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1182\/blood-2002-06-1636","article-title":"Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment","volume":"101","author":"Rubenstein","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2005.05.008_bib28","first-page":"578","article-title":"Results from a phase I study of intraventricular administration of rituximab in patients with recurrent lymphomatous meningitis","volume":"23","author":"Rubenstein","year":"2004","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.hoc.2005.05.008_bib29","first-page":"753","article-title":"Intraventricular treatment of relapsed central nervous system lymphoma with the anti-CD20 antibody rituximab","volume":"89","author":"Schulz","year":"2004","journal-title":"Haematologica"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858805000456?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858805000456?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T11:37:37Z","timestamp":1760182657000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858805000456"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,8]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2005,8]]}},"alternative-id":["S0889858805000456"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2005.05.008","relation":{},"ISSN":["0889-8588"],"issn-type":[{"value":"0889-8588","type":"print"}],"subject":[],"published":{"date-parts":[[2005,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Secondary Central Nervous System Lymphoma: Risk Factors and Prophylaxis","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2005.05.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2005 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}